Compile Data Set for Download or QSAR
Report error Found 102 Enz. Inhib. hit(s) with all data for entry = 12070
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676150(US20240166618, Compound 51)
Affinity DataKi:  0.0400nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674362(US20240166618, Compound 13)
Affinity DataKi:  0.100nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676134(US20240166618, Compound 36 | US20250270173, Compou...)
Affinity DataKi:  0.700nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676153(US20240166618, Compound 54)
Affinity DataKi:  0.760nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM21342((4R,7R)-N,N-diethyl-6-methyl-6,11-diazatetracyclo[...)
Affinity DataKi:  0.890nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent
PDB3D3D Structure (crystal)
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676152(US20240166618, Compound 53)
Affinity DataKi:  0.940nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676156(US20240166618, Compound 57)
Affinity DataKi:  0.970nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676149(US20240166618, Compound 50)
Affinity DataKi:  1.11nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676157(US20240166618, Compound 58)
Affinity DataKi:  1.35nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676155(US20240166618, Compound 56)
Affinity DataKi:  1.53nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676195(US20240166618, Compound 87)
Affinity DataKi:  1.53nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50164318(2-(2,5-Dimethoxy-4-pentylsulfanyl-phenyl)-1-methyl...)
Affinity DataKi:  1.58nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676148(US20240166618, Compound 49)
Affinity DataKi:  1.66nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674363(US20240166618, Compound 14)
Affinity DataKi:  1.74nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674359(US20240166618, Compound 10)
Affinity DataKi:  1.79nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674351(US20240166618, Compound 4ent1)
Affinity DataKi:  1.79nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676161(US20240166618, Compound 61)
Affinity DataKi:  1.99nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50164318(2-(2,5-Dimethoxy-4-pentylsulfanyl-phenyl)-1-methyl...)
Affinity DataKi:  2.03nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676194(US20240166618, Compound 86)
Affinity DataKi:  2.13nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674338(2-(2,5-dimethoxy-4-methylphenyl)-N-(2-methoxybenzy...)
Affinity DataKi:  2.52nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50593194(CHEMBL5184791 | US20240166618, Compound 64)
Affinity DataKi:  2.71nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent
PDB3D3D Structure (crystal)
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676154(US20240166618, Compound 55)
Affinity DataKi:  2.71nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674352(US20240166618, Compound 4ent2)
Affinity DataKi:  3.05nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676193(US20240166618, Compound 85)
Affinity DataKi:  3.39nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674353(US20240166618, Compound 5)
Affinity DataKi:  3.40nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676162(US20240166618, Compound 63)
Affinity DataKi:  3.82nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676137(US20240166618, Compound 39)
Affinity DataKi:  4.46nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674373(US20240166618, Compound 23 | US20240166618, Compou...)
Affinity DataKi:  5.41nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676174(US20240166618, Compound 75)
Affinity DataKi:  5.56nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676200(US20240166618, Compound 94)
Affinity DataKi:  5.66nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50593194(CHEMBL5184791 | US20240166618, Compound 64)
Affinity DataKi:  5.79nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent
PDB3D3D Structure (crystal)
Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50005267(CHEMBL292821 | 2-(4-Bromo-2,5-dimethoxy-phenyl)-et...)
Affinity DataKi:  6.31nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674354(US20240166618, Compound 6 | US20250270173, Compoun...)
Affinity DataKi:  7.10nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676136(US20240166618, Compound 38)
Affinity DataKi:  7.79nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50005267(CHEMBL292821 | 2-(4-Bromo-2,5-dimethoxy-phenyl)-et...)
Affinity DataKi:  8.25nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676138(US20240166618, Compound 40)
Affinity DataKi:  9.06nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674364(US20240166618, Compound 15)
Affinity DataKi:  9.42nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50164338(2-(4-Butylsulfanyl-2,5-dimethoxy-phenyl)-1-methyl-...)
Affinity DataKi:  9.54nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM674365(US20240166618, Compound 16)
Affinity DataKi:  10.8nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676127(US20240166618, Compound 27)
Affinity DataKi:  10.8nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676151(US20240166618, Compound 52)
Affinity DataKi:  14.5nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM28582([125I]2,5-dimethoxy-4-iodoamphetamine | DOI,(-) | ...)
Affinity DataKi:  14.5nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50038370(Racemic DOTFM | 2-(2,5-Dimethoxy-4-trifluoromethyl...)
Affinity DataKi:  15.8nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676173(US20240166618, Compound 74)
Affinity DataKi:  15.9nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50240788(2-(2,5-dimethoxy-4-ethylphenyl)ethylamine | 2-(4-E...)
Affinity DataKi:  16.7nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM50005249(2-(2,5-Dimethoxy-4-propyl-phenyl)-1-methyl-ethylam...)
Affinity DataKi:  17.6nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676130(US20240166618, Compound 30)
Affinity DataKi:  19.4nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676126(US20240166618, Compound 26)
Affinity DataKi:  22.9nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676172(US20240166618, Compound 73)
Affinity DataKi:  23.6nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Target5-hydroxytryptamine receptor 2A(Human)
Gilgamesh Pharmaceuticals

US Patent
LigandPNGBDBM676175(US20240166618, Compound 76)
Affinity DataKi:  24.8nMAssay Description:5-HT2A Receptor Radioligand Binding. Affinity of the test compounds for the 5-HT2A receptor was determined in radioligand binding experiments with [3...More data for this Ligand-Target Pair
In Depth
Date in BDB:
8/26/2024
Entry Details
US Patent

Displayed 1 to 50 (of 102 total ) | Next | Last >>
Jump to: